Sanaa M. Kamal|Bradley S. Turner|Qi He|J. Rasenack|Leonardo Bianchi|Ahmed Al Tawil|Ahmed Nooman|M Massoud|Margaret James Koziel|Nezam H. Afdhal
Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis
Harvard University|Beth Israel Deaconess Medical Center|Ain Shams University|Beth Israel Deaconess Medical Center|Harvard University|Beth Israel Deaconess Medical Center|Harvard University|University of Basel|University of Basel|Ain Shams University|Ain Shams University|Ain Shams University|Beth Israel Deaconess Medical Center|Harvard University|Beth Israel Deaconess Medical Center|Harvard University
serial liver biopsies gold standard progression fibrosis evaluated longitudinal cohort study assessed different rates progression fibrosis using serial liver biopsies serum fibrosis markers ykl40 piiinp cytokines transforming growth factor beta tgf tumor necrosis factor alpha tnf 10year cohort study performed patients hepatitis c virus hcv alone hcv schistosomiasis patients enrolled time acute hcv infection prospectively evaluated two liver biopsies entry end followup true rates progression fibrosis calculated per year serum ykl40 nterminal propeptide collagen iii piiinp tgf tnf measured well expression tgf tnf ykl40 mrna liver tissue significant increase progression rates fibrosis occurred coinfected group 061 013 compared hcv monoinfection group 01 006 p 001 progression fibrosis rateyear direct linear correlation ykl40 r 0892 p 001 piiinp r 0577 p 01 ykl40 showed linear correlation tgf r 0897 p 001 hepatic mrna levels ykl40 tgf correlated serum levels confirming hepatic source elevated serum levels conclusion serial cytokine fibrosis markers accurately determine rate fibrosis progressing identifying rapid fibrosis stable disease hepatology 200643771779